Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical evidence of pulmonary hypertension (PH) requiring INO therapy as prescribed by the attending physician.~2. Indwelling arterial catheter.~3. Signed informed consent~Exclusion Criteria:~1. Clinically unstable circulatory condition requiring epinephrine \> 0.1 mcg/kg/min or levophed, or already meeting treatment failure criteria (see section 5.3 below)~2. Known hypersensitivity to prostacyclin compounds~3. Patients receiving sildenafil or bosentan~4. Refusal by the attending physician

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2: Inhaled Iloprost continuous (Type: EXPERIMENTAL): Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy.
- Phase 1: Inhaled Iloprost 3 doses (Type: EXPERIMENTAL): Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).